Skip to content

US · MIRA · DRUG MANUFACTURERS - GENERAL

MIRA Pharmaceuticals, Inc. (MIRA) intrinsic value and stock valuation

$0.29as of 2026-11-21 · Mkt cap 27.64M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

MIRA Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values MIRA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MIRA’s statements →

MIRA Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - General Miami, FL 33131 mirapharmaceuticals.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$0.00
20202025
Net income
-$-10.44M
20202025
Free cash flow
-$-4.66M
20202025
Total equity
$10.4M
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-10.49M-$-8.02M-$-8.53M-$-7.05M-$-2.15M
Net income-$-10.44M-$-7.85M-$-11.98M-$-7.06M-$-2.18M
EPSd-$-440.69K-$-508.42K-$-645.13K-$-478.64K-$-147.8K
Operating cash flow-$-4.66M-$-5.56M-$-4.53M-$-5.6M-$-1.38M
Capital expenditure$0.00-$0.00$0.00$0.00$0.00
Free cash flow-$-4.66M-$-5.56M-$-4.53M-$-5.6M-$-1.38M
Total assets$11.1M$2.92M$4.93M$860K$3.36M
Total debt$0.00$0.00$10K$490K$290K
Net debt-$-6.35M-$-2.83M-$-4.6M$140K-$-2.52M
Total equity$10.4M$2.2M$4.37M-$-600K$2.26M
Cash and short-term investments$6.35M$2.83M$4.6M$350K$2.81M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$1.72M$3.31M$1.57M$2.35M$680K
Selling, general and administrative expenses$8.77M$4.71M$6.5M$2.99M$770K
Other expenses$0.00$0.00$450K$1.7M$700K
Operating expenses$10.5M$8.02M$8.53M$7.05M$2.15M
Cost and expenses$10.5M$8.02M$8.53M$7.05M$2.15M
Interest income$100K$0.00$0.00$0.00$0.00
Interest expense$0.00$170K$3.46M$10K$20K
Depreciation and amortization$0.00$0.00$0.00$7.05M$2.15M
Ebitda-$-10.44M-$-8.02M-$-8.53M$0.00$0.00
Operating income-$-10.49M-$-8.02M-$-8.53M-$-7.05M-$-2.15M
Total other income/expenses, net$50K$170K-$-3.46M-$-10K-$-20K
Income before tax-$-10.44M-$-7.85M-$-11.98M-$-7.06M-$-2.18M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-10.44M-$-7.85M-$-11.98M-$-7.06M-$-2.18M
Weighted average shares outstanding$23.7M$15.4M$18.6M$14.8M$14.8M
Weighted average diluted shares outstanding$23.7M$15.4M$18.6M$14.8M$14.8M
Balance sheet
20252024202320222021
Cash and short-term investments$6.35M$2.83M$4.6M$350K$2.81M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$11.1M$2.89M$4.86M$490K$2.91M
Property, plant and equipment, net$0.00$0.00$10K$360K$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$40K$0.00$0.00$0.00
Total non-current assets$40K$40K$70K$360K$450K
Total assets$11.1M$2.92M$4.93M$860K$3.36M
Accounts payable$130K$720K$540K$910K$230K
Short-term debt$0.00$0.00$10K$410K$290K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$700K$720K$560K$1.37M$1.09M
Long-term debt$0.00$0.00$0.00$80K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00-$0.00$80K$0.00
Capital lease obligations$0.00$0.00$10K$360K$0.00
Total liabilities$700K$720K$560K$1.45M$1.09M
Common stock$0.00$0.00$0.00$10K$10K
Retained earnings-$-39.58M-$-29.14M-$-21.29M-$-9.3M-$-2.24M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$10.4M$2.2M$4.37M-$-600K$2.26M
Total investments$0.00$40K$0.00$0.00$0.00
Total debt$0.00$0.00$10K$490K$290K
Net debt-$-6.35M-$-2.83M-$-4.6M$140K-$-2.52M
Cash flow statement
20252024202320222021
Net income-$-10.44M-$-7.85M-$-11.98M-$-7.06M-$-2.18M
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Stock-based compensation$6.31M$1.92M$2.55M$1.3M$0.00
Change in working capital-$-570K$370K-$-640K$150K$780K
Accounts receivable$0.00$10K-$-10K$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-590K$180K-$-390K$0.00$0.00
Net cash provided by operating activities-$-4.66M-$-5.56M-$-4.53M-$-5.6M-$-1.38M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$0.00$0.00$0.00
Common stock issued$7.9M$3.61M$7.7M$2.9M$4.5M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$8.18M$3.79M$8.78M$3.15M$4.18M
Net change in cash$3.51M-$-1.77M$4.25M-$-2.46M$2.81M
Cash at end of period$6.35M$2.83M$4.6M$350K$2.81M
Operating cash flow-$-4.66M-$-5.56M-$-4.53M-$-5.6M-$-1.38M
Capital expenditure$0.00-$0.00$0.00$0.00$0.00
Free cash flow-$-4.66M-$-5.56M-$-4.53M-$-5.6M-$-1.38M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About MIRA Pharmaceuticals, Inc.

        MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.

        CEO
        Erez Aminov
        Employees
        2
        Beta
        1.49

        Explore

        Frequently asked questions

        What is the intrinsic value of MIRA Pharmaceuticals, Inc. (MIRA)?

        InvestorsCraft does not currently publish an intrinsic value for MIRA. How the IC value is calculated.

        Is MIRA undervalued?

        InvestorsCraft does not publish an undervaluation signal for MIRA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.